LY2940930

LY2940930 is a potent and selective small molecule inhibitor of Checkpoint kinase 1 (Chk1), a critical mediator of the DNA damage response. Developed by Eli Lilly, the compound is primarily investigated for its ability to sensitize tumor cells, particularly small cell lung cancer (SCLC), to DNA-damaging chemotherapeutic agents like cisplatin. In cells with deficient p53 or Rb pathways, Chk1 inhibition by LY2940930 prevents the necessary cell cycle arrest for DNA repair, leading to the accumulation of DNA damage, decreased E2F1 protein levels, and induction of apoptosis through premature mitotic entry. Research indicates that LY2940930 treatment can lead to increased mitotic markers, such as phospho-histone H3, promoting cell death in cancer cell lines regardless of p53 status.